(R)-3-methylisothiazolidine 1,1-dioxide → (R)-[4-(3-cyclopropyl-5-methylpyridin-2-yl)piperazin-1-yl][2-fluoro-4-(3-methyl-1,1-dioxo-1lambda6-isothiazolidin-2-yl)phenyl]methanone
반응식
[CH:1]1([C:4]2[C:5]([N:11]3[CH2:16][CH2:15][N:14]([C:17]([C:19]4[CH:24]=[CH:23][C:22](I)=[CH:21][C:20]=4[F:26])=[O:18])[CH2:13][CH2:12]3)=[N:6][CH:7]=[C:8]([CH3:10])[CH:9]=2)[CH2:3][CH2:2]1.[CH3:27][C@@H:28]1[CH2:32][CH2:31][S:30](=[O:34])(=[O:33])[NH:29]1>>[CH:1]1([C:4]2[C:5]([N:11]3[CH2:16][CH2:15][N:14]([C:17]([C:19]4[CH:24]=[CH:23][C:22]([N:29]5[C@H:28]([CH3:27])[CH2:32][CH2:31][S:30]5(=[O:34])=[O:33])=[CH:21][C:20]=4[F:26])=[O:18])[CH2:13][CH2:12]3)=[N:6][CH:7]=[C:8]([CH3:10])[CH:9]=2)[CH2:3][CH2:2]1참가 물질
3
반응물 2
생성물 1
실험 절차
Using [4-(3-cyclopropyl-5-methylpyridin-2-yl)piperazin-1-yl](2-fluoro-4-iodophenyl)methanone (627 mg) described in Preparation Example 183 and (R)-3-methylisothiazolidine 1,1-dioxide (182 mg) described in Preparation Example 2 and by the reaction and treatment in the same manner as in Example 1, the title compound (291 mg) was obtained.